Journals / Respiratory Case Reports / 2017 / Cilt: 6 - Sayı: 2

Tüm İlk Seçenek Antitüberküloz İlaçlarına Karşı Fiks İlaç Döküntüsü Gelişen Akciğer Tüberkülozu

Pulmonary Tuberculosis with Fixed Drug Eruption to All First-Line Anti-Tuberculosis Drugs

Pages
82–85
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient's condition deteriorated, he developed severe hypoxemia, and unfortunately, he died during fixed drug eruption treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tuberculosis (TB) is still one of the leading causes of mortality worldwide.
📊
Key Findings & Data:Here, we report rare case of a 34-year-old male who presented with pulmonary TB and fixed drug eruption to all first-line anti-TB therapies.
💡
Conclusion & Impact:The patient's condition deteriorated, he developed severe hypoxemia, and unfortunately, he died during fixed drug eruption treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Tuberculosis (TB) is still one of the leading causes of mortality worldwide. Treatment with anti-TB drugs sometimes results in side effects for patients, including drug reactions, both allergic and non-allergic. Cutaneous adverse drug reaction is the most common side effect of anti-TB drugs, but severe reaction is rare. Here, we report rare case of a 34-year-old male who presented with pulmonary TB and fixed drug eruption to all first-line anti-TB therapies. After ingesting anti-TB regimen, multiple skin erosions and blisters occurred. Skin biopsy was performed and result was epidermis with subepidermal bullous. The patient's condition deteriorated, he developed severe hypoxemia, and unfortunately, he died during fixed drug eruption treatment.

Özet

Tüberküloz tüm Dünya'da önemli bir mortalite nedeni olmaya devam etmektedir. Antitüberküloz tedavi sırasında kullanılan ilaçlarla, allerjik veya non-allerjik reaksiyonlar şeklinde yan etkiler ortaya çıkmaktadır. Ciddi reaksiyonlar nadir görülmekle beraber, ilaca bağlı cilt reaksiyonları antitüberküloz ilaçların en sık görülen yan etkileridir. Burada, ilk seçenek antitüberküloz ilaçların tümüne karşı fiks ilaç döküntüsü olan akciğer tüberkülozlu 34 yaşındaki erkek olguyu sunuyoruz. Antitüberküloz ilaçların alımından sonra hastanın tüm vücudunda çok sayıda erozyon ve kabarcıklar oluştu. Cilt biyopsisi yapıldı ve sonucu epidermal ve sub-epidermal büller olarak tanımlandı. Hastanın durumu ağır hiposemi nedeniyle kötüleşmeye başladı. Ne yazık ki, fiks ilaç döküntüsü tedavisi sırasında hasta vefat etti.

🔖

Cite This Article

AMANDA, G., NURWİDYA, F. (2017). Tüm İlk Seçenek Antitüberküloz İlaçlarına Karşı Fiks İlaç Döküntüsü Gelişen Akciğer Tüberkülozu. Respiratory Case Reports, Cilt: 6 - Sayı: 2, 82–85. https://ajindex.com/articles/302560

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Tan WC, Ong CK, Kang SC, Razak MA. Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. Med J Malaysia 2007; 62:143-6
  2. John SS. Fixed drug eruption due to rifampin. Lepr Rev 1998; 69:397-9. [CrossRef] 3. Scheid P, Kanny G, Trechot P, Rosner V, Menard O, Vignaud JM, et al. Isoniazid-induced bullous skin reaction. Allergy 1999; 54:294-6. [CrossRef] 4. Bakayoko AS, Kaloga M, Kamagate M, Kone Z, Daix AT, Ohui E, et al. Fixed drug eruption after taking ethambutol. Rev Mal Respir 2015; 32:48-51. [CrossRef] 5. Lehloenya RJ, Dheda K. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Rev Anti Infec Ther 2012; 10:475-86. [CrossRef] 6. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011; 71:684-700. [CrossRef] 7. Schnyder B, Brockow K. Pathogenesis of drug allergy - current concepts and recent insights. Clin Exp Allergy 2015; 45:1376-83. [CrossRef] 8. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9:316-21. [CrossRef] 9. Sehgal VN, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol 2006; 45:897-908. [CrossRef] 10. Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2013; 168:726-32. [CrossRef] 11. Nahid P, Jarlsberg LG, Rudoy I, de Jong BC, Unger A, Kawamura LM, et al. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infec Dis 2011; 11:1. [CrossRef] 12. Philadephia tuberculosis control program. Guidelines for the management of adverse drug effects of antimycobacterial agents. Philadelphia: Philadephia tuberculosis control program; 1998. p. 5-6.